News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Trial Data Suggests Major Breakthrough In Treatment Resistant Depression

New Zealand based Douglas Pharmaceuticals Ltd is pleased to announce that a majority of patients with Treatment Resistant Depression experienced rapid relief of their symptoms when treated with R-107 (extended-release oral dose of ketamine) in a Phase 2 study.

The study, R107-C205 (BEDROC), enrolled 234 subjects diagnosed with Treatment Resistant Depression with a mean baseline score of 31 on the Montgomery-Åsberg Depression Rating Scale (MADRS) who had failed to respond to at least two anti-depressants. At the enrichment phase, all patients were dosed with R-107 daily for 5 days and on Day 8 were reassessed, by which time the mean MADRS score had dropped from 31 to 13 with 169 (72%) of the subjects being classified as treatment responders (with a MADRS score 12).

Responders to the enrichment week then entered a double-blinded, randomised and placebo-controlled dose-finding study of 12 weeks duration where they receive R-107 or placebo twice a week.

Top-line safety and efficacy results from this study are expected in November 2021 by which time Douglas Pharmaceuticals intends to commence commercial partnering for NDA (new drug application) enabling Phase 3 trials.

Subjects who complete BEDROC are eligible to enter an open label trial (R107-C206, BEDROC-1) where they are treated with R-107 twice weekly for 6 months. Of the 114 subjects so far treated 50 are in remission (MADRS 10), 96 of subjects have MADRS < 22, while 18 subjects remain severely depressed with MADRS 22.

Douglas Pharmaceuticals Ltd Chief Scientific Officer, Dr Peter Surman, says “The data from the enrichment phase demonstrates a significant and rapid treatment effect and a well-tolerated safety profile in patients with Treatment Resistant Depression.”

He says many patients who complete BEDROC-1 have requested compassionate supply from their primary care physician. Based on the current trend he expects a significant number of those patients randomised in BEDROC will enrol in the compassionate use program following BEDROC-1.

With trial recruitment now complete, Managing Director of Douglas Pharmaceuticals Ltd, Jeff Douglas, says “Clinically meaningful efficacy as an anti-depressant could make R107 an ideal therapy for people who suffer with major depression. The rapid on-set of remission, usually within one to two days of starting therapy, if confirmed, is a major medical breakthrough compared to current oral treatments where patients can take four to six weeks to see a significant improvement in mood.”

Professor Paul Glue, MD, University of Otago and National Lead Investigator for BEDROC, BEDROC-1 says “As a researcher, a psychiatrist and clinician who treats many patients with Treatment Resistant Depression, I am really encouraged by this data,”

Professor Glue adds “The rapid on-set of treatment response with R107 is particularly impressive and, if confirmed, will have a significant impact on the treatment of patients with major depressive disorder as well as those with increased risk of suicidality.”

© Scoop Media

 
 
 
Culture Headlines | Health Headlines | Education Headlines

 


Howard Davis: Emerald Fennell's Promising Young Woman'


The Guardian needed not one, but three reviews to do justice to Fennell's unsettling approach, which indicates exactly how ambiguous and controversial its message really is. More>>


Howard Davis: Jill Trevelyan's Rita Angus

Although Angus has become one of Aotearoa’s best-loved painters, the story of her life remained little known and poorly understood before Jill Trevelyan's acclaimed and revelatory biography, which won the Non Fiction Award at the Montana New Zealand Book Awards in 2009, and has now been republished by Te Papa press. More>>

Howard Davis: The Back of the Painting

Painting conservators are the forensic pathologists of the art world. While they cannot bring their subjects back to life, they do provide fascinating insights into the precise circumstances of a painting's creation, its material authenticity, and constructive methodology. More>>


Howard Davis: Black Panthers on the Prowl

A passionate and gripping political drama from Shaka King, this is an informative and instructive tale of human frailty that centers around the charismatic Chicago Black Panther leader Fred Hampton, who was murdered at the age of twenty-one during a police raid. More>>

Howard Davis: Controlling the High Ground

Stephen Johnson's raw and angry film not only poses important questions with scrupulous authenticity, but also provides a timely reminder of the genocidal consequences of casual bigotry and xenophobia. More>>

Howard Davis: Dryzabone - Robert Conolly's The Dry

After the terrible devastation caused by last year’s bushfires, which prompted hundreds of Australians to shelter in the ocean to escape incineration and destroyed uncountable amounts of wildlife, The Dry has been released during a totally different kind of dry spell. More>>


Howard Davis: Hit the Road, Jack - Chloé Zhao's Nomadland

Nomadland is perhaps the ultimately 'road' movie as it follows a group of dispossessed and disenfranchised vagabonds who find a form of communal refuge in camp sites and trailer parks after the economic contraction of 2008. More>>

 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland